https://www.selleckchem.com/pr....oducts/super-tdu.htm
Serum infliximab trough level(S-IFX) and antibody were documented to correlate with clinical response. The aim of this study was to identify the relationship between early S-IFX, early mucosal healing (MH) and one-year outcome in a cohort on maintenance IFX therapy in Crohn's disease (CD). The study group comprised of retrospectively enrolled patients diagnosed for Crohn's disease ( = 108). Patients received scheduled maintenance therapy after response to IFX induction, and had undergone the early S-IFX test and endoscopic examinatio
Like
Comment
Share
